Abstract
Background Compartmental models dominate epidemic modeling. Estimations of transmission parameters between compartments are typically done through stochastic parameterization processes that depend upon detailed statistics on transmission characteristics, which are economically and resource-wide expensive to collect.
Objectives We apply deep learning techniques as a lower data dependency alternative to estimate transmission parameters of a customized compartmental model, for the purpose of simulating the dynamics of the Omicron phase of the COVID-19 epidemics and projecting its further development in China and subregions within the country.
Methods We construct a compartmental model, and develop a multivariate, multistep deep learning methodology to estimate the model’s transmission parameters. We then feed the estimated transmission parameters to the compartmental model to predict the development of the COVID-19 epidemics in China and subregions within the country for 28 days.
Results In China (excluding Hong Kong and Taiwan), the daily Omicron infection increase is between 60 and 260 in the 28-day forecast period between June 4 and July 1, 2022. On July 1, 2022, there would be 768,622 cumulative confirmed cases and 591 cumulative deceased cases. The CFR would stabilize at 0.077%±0.00025%. Assuming a 25% infection rate, the total deaths with Omicron would be up to 280,000 without non-pharmaceutical intervention (NPI).
Conclusions Current compartmental models require stochastic parameterization to estimate the transmission parameters. These models’ effectiveness depends upon detailed statistics on transmission characteristics. As an alternative, deep learning techniques are effective in estimating these stochastic parameters with greatly reduced dependency on data particularity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NA
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
datasets extracted from JHU CSSE and Tencent
